| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antidepressive Agents | 16 | 2026 | 321 | 3.740 |
Why?
|
| Antipsychotic Agents | 19 | 2019 | 375 | 2.420 |
Why?
|
| Liver Diseases | 11 | 2026 | 385 | 2.040 |
Why?
|
| Coronary Vessel Anomalies | 14 | 2023 | 279 | 1.800 |
Why?
|
| Computed Tomography Angiography | 15 | 2025 | 216 | 1.740 |
Why?
|
| Schizophrenia | 12 | 2017 | 324 | 1.730 |
Why?
|
| Cystic Fibrosis | 8 | 2026 | 268 | 1.640 |
Why?
|
| Bipolar Disorder | 11 | 2021 | 350 | 1.460 |
Why?
|
| Hepatoblastoma | 10 | 2026 | 204 | 1.340 |
Why?
|
| Liver Neoplasms | 15 | 2026 | 1373 | 1.300 |
Why?
|
| Piperazines | 8 | 2025 | 265 | 1.270 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2026 | 161 | 1.190 |
Why?
|
| Liver | 12 | 2026 | 1796 | 0.990 |
Why?
|
| Ketamine | 4 | 2022 | 206 | 0.950 |
Why?
|
| Piperidines | 2 | 2026 | 223 | 0.940 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2022 | 131 | 0.910 |
Why?
|
| Drug Substitution | 1 | 2025 | 27 | 0.890 |
Why?
|
| Renal Artery Obstruction | 2 | 2021 | 40 | 0.840 |
Why?
|
| Health Resources | 1 | 2025 | 131 | 0.820 |
Why?
|
| Quinolones | 3 | 2025 | 60 | 0.750 |
Why?
|
| Rhabdomyoma | 1 | 2022 | 15 | 0.740 |
Why?
|
| Coronary Angiography | 11 | 2025 | 450 | 0.720 |
Why?
|
| Humans | 130 | 2026 | 131163 | 0.710 |
Why?
|
| Health Care Costs | 1 | 2025 | 407 | 0.690 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 3763 | 0.680 |
Why?
|
| Heart Neoplasms | 1 | 2022 | 106 | 0.670 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 147 | 0.660 |
Why?
|
| Psychotropic Drugs | 4 | 2018 | 123 | 0.640 |
Why?
|
| Psychotic Disorders | 4 | 2007 | 146 | 0.630 |
Why?
|
| Thiazoles | 4 | 2015 | 113 | 0.600 |
Why?
|
| Child | 50 | 2026 | 26341 | 0.570 |
Why?
|
| Paroxetine | 5 | 2009 | 24 | 0.570 |
Why?
|
| Drug Therapy, Combination | 7 | 2026 | 1173 | 0.550 |
Why?
|
| Vascular Malformations | 5 | 2022 | 103 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 789 | 0.530 |
Why?
|
| Coronary Artery Disease | 5 | 2023 | 887 | 0.530 |
Why?
|
| Treatment Outcome | 33 | 2026 | 12936 | 0.510 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 58 | 0.500 |
Why?
|
| Psychiatric Status Rating Scales | 11 | 2026 | 830 | 0.500 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2024 | 268 | 0.500 |
Why?
|
| Male | 68 | 2026 | 64957 | 0.500 |
Why?
|
| Jejunal Diseases | 1 | 2016 | 11 | 0.490 |
Why?
|
| Myocardial Perfusion Imaging | 7 | 2024 | 60 | 0.490 |
Why?
|
| Double-Blind Method | 14 | 2026 | 1626 | 0.480 |
Why?
|
| Coronary Vessels | 6 | 2023 | 521 | 0.470 |
Why?
|
| Colonic Diseases | 1 | 2016 | 38 | 0.470 |
Why?
|
| Fistula | 1 | 2016 | 50 | 0.470 |
Why?
|
| Drug Discovery | 1 | 2017 | 179 | 0.460 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 92 | 0.450 |
Why?
|
| Dibenzothiazepines | 1 | 2015 | 11 | 0.440 |
Why?
|
| Female | 63 | 2026 | 70963 | 0.440 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 307 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 386 | 0.430 |
Why?
|
| Embolization, Therapeutic | 4 | 2025 | 233 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 1267 | 0.410 |
Why?
|
| Aorta, Thoracic | 4 | 2021 | 530 | 0.400 |
Why?
|
| Sarcoma | 1 | 2016 | 219 | 0.400 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2025 | 982 | 0.390 |
Why?
|
| Adult | 33 | 2026 | 31282 | 0.390 |
Why?
|
| Adolescent | 28 | 2026 | 20987 | 0.370 |
Why?
|
| Contrast Media | 7 | 2025 | 474 | 0.360 |
Why?
|
| Prospective Studies | 17 | 2026 | 6459 | 0.360 |
Why?
|
| Aorta | 8 | 2023 | 521 | 0.350 |
Why?
|
| Depression | 5 | 2022 | 1320 | 0.340 |
Why?
|
| Hepatectomy | 4 | 2026 | 131 | 0.340 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2026 | 32 | 0.340 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2023 | 176 | 0.340 |
Why?
|
| Pyrazoles | 3 | 2025 | 349 | 0.330 |
Why?
|
| Liver Transplantation | 5 | 2025 | 1147 | 0.330 |
Why?
|
| Middle Aged | 27 | 2026 | 28601 | 0.310 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 61 | 0.310 |
Why?
|
| Heart Defects, Congenital | 5 | 2025 | 1889 | 0.300 |
Why?
|
| Retrospective Studies | 25 | 2026 | 17753 | 0.300 |
Why?
|
| Indoles | 2 | 2025 | 200 | 0.300 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2009 | 215 | 0.300 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2022 | 150 | 0.300 |
Why?
|
| Patient Care Team | 3 | 2020 | 562 | 0.290 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2006 | 13 | 0.290 |
Why?
|
| Child, Preschool | 21 | 2026 | 15110 | 0.290 |
Why?
|
| Health Status | 3 | 2022 | 378 | 0.280 |
Why?
|
| Aged | 11 | 2026 | 21025 | 0.280 |
Why?
|
| Infant | 19 | 2026 | 13352 | 0.280 |
Why?
|
| Heart Ventricles | 3 | 2023 | 749 | 0.270 |
Why?
|
| Patient Compliance | 3 | 2006 | 463 | 0.270 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2025 | 8 | 0.260 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2009 | 30 | 0.260 |
Why?
|
| Delayed-Action Preparations | 9 | 2017 | 123 | 0.250 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 305 | 0.240 |
Why?
|
| Selegiline | 1 | 2006 | 8 | 0.240 |
Why?
|
| Central Nervous System Stimulants | 3 | 2016 | 133 | 0.240 |
Why?
|
| Cyclohexanols | 2 | 2003 | 9 | 0.240 |
Why?
|
| Aripiprazole | 2 | 2017 | 22 | 0.240 |
Why?
|
| Postoperative Complications | 6 | 2026 | 3147 | 0.240 |
Why?
|
| Yttrium Radioisotopes | 2 | 2025 | 22 | 0.230 |
Why?
|
| Aminophenols | 1 | 2025 | 14 | 0.230 |
Why?
|
| Benzodioxoles | 1 | 2025 | 17 | 0.230 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 299 | 0.230 |
Why?
|
| Organ Sparing Treatments | 1 | 2026 | 46 | 0.230 |
Why?
|
| Pyrrolidines | 1 | 2025 | 49 | 0.230 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 42 | 0.220 |
Why?
|
| Anhedonia | 1 | 2025 | 38 | 0.220 |
Why?
|
| Young Adult | 9 | 2026 | 10103 | 0.220 |
Why?
|
| Mood Disorders | 3 | 2022 | 129 | 0.220 |
Why?
|
| Hemangioendothelioma | 2 | 2022 | 24 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2023 | 2065 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 36 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1295 | 0.210 |
Why?
|
| Predictive Value of Tests | 8 | 2023 | 2304 | 0.210 |
Why?
|
| Depressive Disorder | 2 | 2009 | 460 | 0.210 |
Why?
|
| Fibromyalgia | 3 | 2009 | 20 | 0.210 |
Why?
|
| Exercise | 2 | 2021 | 892 | 0.210 |
Why?
|
| Pyridines | 1 | 2025 | 255 | 0.210 |
Why?
|
| Cardiac Catheterization | 4 | 2024 | 630 | 0.200 |
Why?
|
| Interleukin-15 | 1 | 2024 | 104 | 0.200 |
Why?
|
| Myocardial Bridging | 1 | 2024 | 14 | 0.200 |
Why?
|
| Schizophrenic Psychology | 2 | 2017 | 81 | 0.200 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 143 | 0.200 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1882 | 0.200 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 4066 | 0.190 |
Why?
|
| Informed Consent | 3 | 2008 | 351 | 0.190 |
Why?
|
| Replantation | 2 | 2021 | 51 | 0.190 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 54 | 0.190 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 23 | 0.190 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2021 | 83 | 0.190 |
Why?
|
| Heart Diseases | 2 | 2025 | 499 | 0.190 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2002 | 14 | 0.190 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2023 | 45 | 0.190 |
Why?
|
| Mianserin | 1 | 2002 | 3 | 0.190 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 903 | 0.190 |
Why?
|
| Surface Plasmon Resonance | 1 | 2022 | 54 | 0.190 |
Why?
|
| Bupropion | 1 | 2002 | 27 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 402 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 2833 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 1129 | 0.180 |
Why?
|
| Angiography | 4 | 2023 | 179 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2020 | 1246 | 0.180 |
Why?
|
| Aneurysm, False | 1 | 2023 | 84 | 0.180 |
Why?
|
| Administration, Intranasal | 1 | 2022 | 130 | 0.180 |
Why?
|
| Ductus Arteriosus | 1 | 2022 | 59 | 0.180 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2019 | 13 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 265 | 0.180 |
Why?
|
| Aging | 2 | 2019 | 1242 | 0.180 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 72 | 0.170 |
Why?
|
| Triazoles | 1 | 2002 | 141 | 0.170 |
Why?
|
| Hypertension, Portal | 1 | 2022 | 78 | 0.170 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 731 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 369 | 0.170 |
Why?
|
| Renal Artery | 1 | 2021 | 74 | 0.170 |
Why?
|
| Purines | 2 | 2019 | 118 | 0.170 |
Why?
|
| Prognosis | 5 | 2023 | 4886 | 0.160 |
Why?
|
| Receptors, sigma | 2 | 2017 | 7 | 0.160 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 6 | 0.160 |
Why?
|
| Radiology Department, Hospital | 1 | 2020 | 26 | 0.160 |
Why?
|
| Follow-Up Studies | 7 | 2026 | 5196 | 0.160 |
Why?
|
| Liver Glycogen | 1 | 2020 | 20 | 0.160 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2019 | 8 | 0.160 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 19 | 0.150 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 29 | 0.150 |
Why?
|
| Ultrasonography | 4 | 2021 | 943 | 0.150 |
Why?
|
| Norwood Procedures | 1 | 2021 | 96 | 0.150 |
Why?
|
| Models, Anatomic | 1 | 2020 | 105 | 0.150 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 88 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 83 | 0.150 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 15 | 0.150 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 30 | 0.150 |
Why?
|
| Positive-Pressure Respiration | 1 | 2019 | 84 | 0.150 |
Why?
|
| Neurosciences | 1 | 2019 | 53 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 124 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2023 | 356 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 441 | 0.140 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 78 | 0.140 |
Why?
|
| Disease Progression | 2 | 2026 | 2200 | 0.140 |
Why?
|
| Cystine Depleting Agents | 1 | 2018 | 3 | 0.140 |
Why?
|
| Lymphography | 1 | 2018 | 9 | 0.140 |
Why?
|
| Biomarkers | 6 | 2026 | 3385 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 104 | 0.140 |
Why?
|
| Cysteamine | 1 | 2018 | 16 | 0.140 |
Why?
|
| Lymphatic Diseases | 1 | 2018 | 28 | 0.130 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 23 | 0.130 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8635 | 0.130 |
Why?
|
| Paliperidone Palmitate | 1 | 2017 | 4 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 387 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2009 | 58 | 0.130 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2021 | 261 | 0.130 |
Why?
|
| Umbilical Veins | 1 | 2017 | 61 | 0.130 |
Why?
|
| Coronary Sinus | 1 | 2017 | 12 | 0.130 |
Why?
|
| Hemangioma | 1 | 2018 | 86 | 0.130 |
Why?
|
| Mental Competency | 1 | 1998 | 55 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 182 | 0.130 |
Why?
|
| Drug Evaluation | 1 | 2017 | 101 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 3061 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 307 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 960 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 1168 | 0.130 |
Why?
|
| Quality of Life | 3 | 2022 | 2082 | 0.130 |
Why?
|
| Dopamine Antagonists | 1 | 2017 | 38 | 0.130 |
Why?
|
| Serotonin Agents | 1 | 2017 | 14 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 1224 | 0.130 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2017 | 23 | 0.130 |
Why?
|
| Image Enhancement | 1 | 2018 | 159 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 468 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2019 | 190 | 0.120 |
Why?
|
| Chest Pain | 1 | 2017 | 133 | 0.120 |
Why?
|
| Thiophenes | 1 | 2017 | 69 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 214 | 0.120 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2016 | 13 | 0.120 |
Why?
|
| Hospitalization | 1 | 2025 | 1950 | 0.120 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2019 | 222 | 0.120 |
Why?
|
| Exercise Test | 3 | 2024 | 239 | 0.120 |
Why?
|
| Gastroscopy | 1 | 2016 | 98 | 0.120 |
Why?
|
| Electroconvulsive Therapy | 1 | 2017 | 82 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 283 | 0.120 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 79 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1722 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2016 | 81 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| Child Abuse | 2 | 2009 | 228 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 3 | 0.110 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 75 | 0.110 |
Why?
|
| Aggression | 1 | 2017 | 218 | 0.110 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 19 | 0.110 |
Why?
|
| Pain Measurement | 4 | 2009 | 353 | 0.110 |
Why?
|
| Quetiapine Fumarate | 1 | 2015 | 14 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 21 | 0.110 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 29 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2018 | 299 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 534 | 0.110 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.110 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 41 | 0.110 |
Why?
|
| Margins of Excision | 2 | 2026 | 60 | 0.110 |
Why?
|
| Respiration | 1 | 2015 | 117 | 0.100 |
Why?
|
| Acetylcarnitine | 1 | 2014 | 3 | 0.100 |
Why?
|
| Risk Factors | 6 | 2020 | 11074 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 338 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2015 | 154 | 0.100 |
Why?
|
| Thrombosis | 1 | 2019 | 499 | 0.100 |
Why?
|
| Isoindoles | 1 | 2013 | 4 | 0.100 |
Why?
|
| Stents | 1 | 2020 | 799 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 36 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2013 | 32 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 1998 | 564 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2006 | 237 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 248 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 47 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 225 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 123 | 0.100 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2003 | 20 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.100 |
Why?
|
| Echocardiography | 4 | 2023 | 1125 | 0.100 |
Why?
|
| ROC Curve | 2 | 2014 | 613 | 0.090 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2017 | 401 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1216 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2015 | 319 | 0.090 |
Why?
|
| Appendicitis | 1 | 2014 | 132 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 221 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2015 | 168 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 230 | 0.090 |
Why?
|
| Imidazoles | 1 | 2013 | 219 | 0.090 |
Why?
|
| Subclavian Artery | 1 | 2012 | 63 | 0.090 |
Why?
|
| Weight Gain | 2 | 2006 | 393 | 0.090 |
Why?
|
| Lung | 1 | 2019 | 1535 | 0.090 |
Why?
|
| Child Abuse, Sexual | 2 | 2009 | 68 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 619 | 0.080 |
Why?
|
| Genotype | 4 | 2018 | 2595 | 0.080 |
Why?
|
| Republic of Korea | 3 | 2017 | 50 | 0.080 |
Why?
|
| Proxy | 1 | 2010 | 21 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 6196 | 0.080 |
Why?
|
| New York | 2 | 2002 | 69 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2020 | 3359 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2009 | 928 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 663 | 0.080 |
Why?
|
| Psychophysiologic Disorders | 1 | 2009 | 25 | 0.070 |
Why?
|
| Neoplasms | 1 | 2024 | 3016 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2010 | 217 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 3829 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2026 | 1490 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2085 | 0.070 |
Why?
|
| Placebos | 1 | 2009 | 223 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2021 | 371 | 0.070 |
Why?
|
| Outpatients | 1 | 2009 | 262 | 0.070 |
Why?
|
| Polypharmacy | 1 | 2007 | 36 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 563 | 0.070 |
Why?
|
| Naltrexone | 1 | 2007 | 68 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2015 | 844 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 3711 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2024 | 810 | 0.060 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2007 | 37 | 0.060 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 81 | 0.060 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 54 | 0.060 |
Why?
|
| Tranylcypromine | 1 | 2006 | 1 | 0.060 |
Why?
|
| Phenelzine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Parenchymal Tissue | 1 | 2026 | 8 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 63 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 963 | 0.060 |
Why?
|
| Chloride Channel Agonists | 1 | 2025 | 8 | 0.060 |
Why?
|
| Hyperprolactinemia | 1 | 2005 | 23 | 0.060 |
Why?
|
| Psychiatry | 1 | 2008 | 272 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1545 | 0.060 |
Why?
|
| Alcoholism | 1 | 2007 | 244 | 0.050 |
Why?
|
| Heart | 2 | 2021 | 650 | 0.050 |
Why?
|
| Reoperation | 2 | 2021 | 818 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2025 | 270 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 1459 | 0.050 |
Why?
|
| Quinolines | 1 | 2025 | 118 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5063 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 716 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1618 | 0.050 |
Why?
|
| Myocardium | 1 | 2009 | 852 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 1239 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2026 | 905 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2009 | 536 | 0.050 |
Why?
|
| Pulmonary Artery | 2 | 2023 | 434 | 0.050 |
Why?
|
| Buspirone | 1 | 2003 | 15 | 0.050 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 20 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1272 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 29 | 0.050 |
Why?
|
| Comorbidity | 2 | 2007 | 1595 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 2017 | 185 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 78 | 0.050 |
Why?
|
| Platelet Count | 1 | 2023 | 139 | 0.050 |
Why?
|
| Obesity | 2 | 2005 | 2426 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 6797 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 412 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2018 | 352 | 0.050 |
Why?
|
| Family | 1 | 2006 | 589 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 567 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 501 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 138 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 106 | 0.040 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 176 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 169 | 0.040 |
Why?
|
| Dobutamine | 1 | 2021 | 48 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 51 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2021 | 59 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2020 | 41 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 34 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2021 | 76 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 36 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 541 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 824 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2020 | 28 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 239 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 395 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2003 | 218 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2020 | 970 | 0.040 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 78 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2020 | 29 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 161 | 0.040 |
Why?
|
| Ischemia | 1 | 2023 | 359 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2004 | 477 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 53 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 125 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1489 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 209 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 153 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 80 | 0.040 |
Why?
|
| Prolactin | 1 | 2019 | 142 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 1445 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2017 | 1483 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2023 | 492 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 549 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 171 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 33912 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 254 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2018 | 47 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 216 | 0.030 |
Why?
|
| Chylous Ascites | 1 | 2018 | 9 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 999 | 0.030 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 15 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 587 | 0.030 |
Why?
|
| Chylothorax | 1 | 2018 | 27 | 0.030 |
Why?
|
| Ligation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2017 | 19 | 0.030 |
Why?
|
| Survivors | 1 | 2020 | 344 | 0.030 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2017 | 52 | 0.030 |
Why?
|
| Publication Bias | 1 | 2017 | 17 | 0.030 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2017 | 15 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2018 | 187 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 191 | 0.030 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2017 | 6 | 0.030 |
Why?
|
| Protons | 1 | 2018 | 94 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 107 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 314 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1998 | 80 | 0.030 |
Why?
|
| Psychopathology | 1 | 2017 | 31 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2017 | 40 | 0.030 |
Why?
|
| Italy | 1 | 2017 | 109 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 27 | 0.030 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 71 | 0.030 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 118 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 151 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 293 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 443 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 245 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 639 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 889 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 515 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 156 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 429 | 0.030 |
Why?
|
| United States | 3 | 2018 | 12072 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 33 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 631 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 808 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 577 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 819 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2015 | 49 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 192 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 258 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 123 | 0.030 |
Why?
|
| Dibenzocycloheptenes | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2013 | 3 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 316 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1998 | 514 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 131 | 0.020 |
Why?
|
| Drug Approval | 1 | 2013 | 48 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 2825 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2015 | 729 | 0.020 |
Why?
|
| Cytokines | 1 | 2019 | 1339 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1680 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 822 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 3360 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 113 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1634 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 345 | 0.020 |
Why?
|
| Intestines | 1 | 2015 | 587 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 132 | 0.020 |
Why?
|
| Alleles | 1 | 2015 | 1673 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 34 | 0.020 |
Why?
|
| Mental Disorders | 1 | 1998 | 910 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4697 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 101 | 0.020 |
Why?
|
| Sick Role | 1 | 2009 | 27 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 1153 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2008 | 30 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1833 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1252 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 73 | 0.020 |
Why?
|
| South Carolina | 1 | 2007 | 10 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 191 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2007 | 14 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2007 | 12 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2007 | 112 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 164 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4497 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 118 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3436 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2005 | 29 | 0.010 |
Why?
|
| Psychometrics | 1 | 2009 | 678 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 351 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 226 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 743 | 0.010 |
Why?
|
| Pregnancy | 2 | 2007 | 7512 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 623 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 732 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 761 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 462 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2904 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 18301 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1211 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 872 | 0.010 |
Why?
|